Corline Biomedical AB
SSE:CLBIO.ST
13.8 (SEK) • At close February 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Corline Biomedical AB |
Symbool | CLBIO.ST |
Munteenheid | SEK |
Prijs | 13.8 |
Beurswaarde | 296,573,040 |
Dividendpercentage | 0% |
52-weken bereik | 8.92 - 19.85 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Henrik Nittmar Ph.D. |
Website | https://www.corline.se |
An error occurred while fetching data.
Over Corline Biomedical AB
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (SEK)
Cijfers zijn in miljoenen (SEK)